ADVANCED PHARMACOLOGY FINAL EXAM UTA
2026-27 ACTUAL EXAM WITH FULL SECTIONS 1-8
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–Q25)
Q1. Define pharmacokinetics.
ANSWER: The study of what the body does to the drug - encompassing
Absorption, Distribution, Metabolism, and Excretion (ADME). Rationale:
Pharmacokinetics describes how the body processes a medication from
administration to elimination. It determines drug concentration at the site of
action over time.
Q2. What are the four major pharmacokinetic processes?
ANSWER: Absorption, Distribution, Metabolism, and Excretion
(ADME). Rationale: These four processes collectively determine drug
bioavailability, duration of action, and elimination from the body.
Q3. Define pharmacodynamics.
ANSWER: The study of what the drug does to the body - including receptor
,binding, post-receptor effects, and clinical response. Rationale:
Pharmacodynamics explains the mechanism of action and the relationship
between drug concentration and therapeutic effect.
Q4. A drug reaches steady-state concentration in approximately how many
half-lives?
ANSWER: Approximately five half-lives. Rationale: After 4 half-lives ~94% of
steady state is achieved; after 5 half-lives >97% is reached. This is why drugs
may take several days to reach full therapeutic effect with regular dosing.
Q5. A drug has a half-life of 8 hours. How long will it take to reach steady-
state concentration?
ANSWER: 40 hours (5 × 8 hours). Rationale: Steady state is reached after
approximately 5 half-lives regardless of the specific drug. This calculation is
essential for determining when therapeutic monitoring should begin.
Q6. What is bioavailability?
ANSWER: The percentage of the administered dose that reaches systemic
circulation unchanged. Rationale: Bioavailability is affected by first-pass
metabolism, drug formulation, and route of administration. IV drugs have 100%
bioavailability; oral drugs have variable bioavailability.
, Q7. What is the therapeutic index?
ANSWER: The margin of safety between effective and toxic doses, calculated
as TD50/ED50. Rationale: A narrow therapeutic index means a small difference
between therapeutic and toxic doses, requiring careful monitoring (e.g.,
warfarin, digoxin, phenytoin).
Q8. What is the therapeutic range?
ANSWER: The plasma drug concentration between the minimum effective
concentration and the minimum toxic concentration. Rationale: Maintaining
drug levels within this window maximizes therapeutic benefit while minimizing
toxicity. Drugs with narrow therapeutic windows require routine monitoring.
Q9. What is volume of distribution (Vd)?
ANSWER: The theoretical volume that would be necessary to contain the
total amount of administered drug at the same concentration observed in
plasma. Rationale: Vd = amount of drug in body / plasma concentration. High
Vd indicates extensive tissue binding; low Vd indicates drug remains primarily in
circulation.
Q10. A drug with low lipid solubility and high plasma protein binding would
have what type of Vd?
ANSWER: A small (low) volume of distribution. Rationale: Low lipid solubility
2026-27 ACTUAL EXAM WITH FULL SECTIONS 1-8
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–Q25)
Q1. Define pharmacokinetics.
ANSWER: The study of what the body does to the drug - encompassing
Absorption, Distribution, Metabolism, and Excretion (ADME). Rationale:
Pharmacokinetics describes how the body processes a medication from
administration to elimination. It determines drug concentration at the site of
action over time.
Q2. What are the four major pharmacokinetic processes?
ANSWER: Absorption, Distribution, Metabolism, and Excretion
(ADME). Rationale: These four processes collectively determine drug
bioavailability, duration of action, and elimination from the body.
Q3. Define pharmacodynamics.
ANSWER: The study of what the drug does to the body - including receptor
,binding, post-receptor effects, and clinical response. Rationale:
Pharmacodynamics explains the mechanism of action and the relationship
between drug concentration and therapeutic effect.
Q4. A drug reaches steady-state concentration in approximately how many
half-lives?
ANSWER: Approximately five half-lives. Rationale: After 4 half-lives ~94% of
steady state is achieved; after 5 half-lives >97% is reached. This is why drugs
may take several days to reach full therapeutic effect with regular dosing.
Q5. A drug has a half-life of 8 hours. How long will it take to reach steady-
state concentration?
ANSWER: 40 hours (5 × 8 hours). Rationale: Steady state is reached after
approximately 5 half-lives regardless of the specific drug. This calculation is
essential for determining when therapeutic monitoring should begin.
Q6. What is bioavailability?
ANSWER: The percentage of the administered dose that reaches systemic
circulation unchanged. Rationale: Bioavailability is affected by first-pass
metabolism, drug formulation, and route of administration. IV drugs have 100%
bioavailability; oral drugs have variable bioavailability.
, Q7. What is the therapeutic index?
ANSWER: The margin of safety between effective and toxic doses, calculated
as TD50/ED50. Rationale: A narrow therapeutic index means a small difference
between therapeutic and toxic doses, requiring careful monitoring (e.g.,
warfarin, digoxin, phenytoin).
Q8. What is the therapeutic range?
ANSWER: The plasma drug concentration between the minimum effective
concentration and the minimum toxic concentration. Rationale: Maintaining
drug levels within this window maximizes therapeutic benefit while minimizing
toxicity. Drugs with narrow therapeutic windows require routine monitoring.
Q9. What is volume of distribution (Vd)?
ANSWER: The theoretical volume that would be necessary to contain the
total amount of administered drug at the same concentration observed in
plasma. Rationale: Vd = amount of drug in body / plasma concentration. High
Vd indicates extensive tissue binding; low Vd indicates drug remains primarily in
circulation.
Q10. A drug with low lipid solubility and high plasma protein binding would
have what type of Vd?
ANSWER: A small (low) volume of distribution. Rationale: Low lipid solubility
